Compare DOMO & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMO | STIM |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.7M | 120.4M |
| IPO Year | 2018 | 2018 |
| Metric | DOMO | STIM |
|---|---|---|
| Price | $3.84 | $2.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $10.28 | $3.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 05-20-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.92 | ★ 57.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,857,000.00 | $52,776,000.00 |
| Revenue This Year | $3.41 | $11.10 |
| Revenue Next Year | $4.72 | $11.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.84 | $0.80 |
| 52 Week High | $18.49 | $3.44 |
| Indicator | DOMO | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 50.50 |
| Support Level | $3.32 | $2.67 |
| Resistance Level | $4.05 | N/A |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 75.31 | 23.73 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.